1. Home
  2. CRSP vs RDNT Comparison

CRSP vs RDNT Comparison

Compare CRSP & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • RDNT
  • Stock Information
  • Founded
  • CRSP 2013
  • RDNT 1985
  • Country
  • CRSP Switzerland
  • RDNT United States
  • Employees
  • CRSP N/A
  • RDNT N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • RDNT Medical Specialities
  • Sector
  • CRSP Health Care
  • RDNT Health Care
  • Exchange
  • CRSP Nasdaq
  • RDNT Nasdaq
  • Market Cap
  • CRSP 3.4B
  • RDNT 3.7B
  • IPO Year
  • CRSP 2016
  • RDNT 1986
  • Fundamental
  • Price
  • CRSP $37.77
  • RDNT $49.78
  • Analyst Decision
  • CRSP Buy
  • RDNT Strong Buy
  • Analyst Count
  • CRSP 19
  • RDNT 4
  • Target Price
  • CRSP $74.35
  • RDNT $69.75
  • AVG Volume (30 Days)
  • CRSP 2.4M
  • RDNT 892.4K
  • Earning Date
  • CRSP 05-07-2025
  • RDNT 05-07-2025
  • Dividend Yield
  • CRSP N/A
  • RDNT N/A
  • EPS Growth
  • CRSP N/A
  • RDNT N/A
  • EPS
  • CRSP N/A
  • RDNT 0.04
  • Revenue
  • CRSP $37,314,000.00
  • RDNT $1,829,664,000.00
  • Revenue This Year
  • CRSP $51.35
  • RDNT $7.83
  • Revenue Next Year
  • CRSP $282.16
  • RDNT $8.87
  • P/E Ratio
  • CRSP N/A
  • RDNT $1,319.66
  • Revenue Growth
  • CRSP N/A
  • RDNT 13.18
  • 52 Week Low
  • CRSP $30.04
  • RDNT $45.00
  • 52 Week High
  • CRSP $67.88
  • RDNT $93.65
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 49.46
  • RDNT 44.21
  • Support Level
  • CRSP $36.74
  • RDNT $47.03
  • Resistance Level
  • CRSP $40.13
  • RDNT $54.99
  • Average True Range (ATR)
  • CRSP 2.67
  • RDNT 3.44
  • MACD
  • CRSP 0.72
  • RDNT 0.35
  • Stochastic Oscillator
  • CRSP 76.62
  • RDNT 47.84

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About RDNT RadNet Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.

Share on Social Networks: